New Publication on TLX250-Px’s Potential in Kidney Cancer Diagnosis
Telix Pharmaceuticals Limited announced a publication of an independent analysis of Phase 3 ZIRCON trial data, which shows that TLX250-Px (Zircaix®) PET/CT imaging is highly predictive of renal malignancy across all renal cancer subtypes, not just clear cell renal cell carcinoma (ccRCC). The analysis revealed a positive predictive value of 98% for malignancy, supporting further evaluation of TLX250-Px in managing non-clear cell renal cell carcinoma. Experts emphasized the utility of the compound in distinguishing aggressive from indolent tumors, aiding in treatment decisions.
MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology1, demonstrating that TLX250-Px (Zircaix®2, 89Zr-girentuximab) PET/CT3 imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC).